Radioimmunotherapy of PANC-1 human pancreatic cancer xenografts in NOD/SCID or NRG mice with Panitumumab labeled with Auger electron emitting, ¹¹¹In or β-particle emitting, ¹⁷⁷Lu.

ABSTRACT:

Background

Epidermal growth factor receptors (EGFR) are overexpressed on > 90% of pancreatic cancers (PnCa) and represent an attractive target for the development of novel therapies, including radioimmunotherapy (RIT). Our aim was to study RIT of subcutaneous (s.c.) PANC-1 human PnCa xenografts in mice using the anti-EGFR monoclonal antibody, panitumumab labeled with Auger electron (AE)-emitting, ¹¹¹In or β-particle emitting, ¹⁷⁷Lu at amounts that were non-toxic to normal tissues.

Results

Panitumumab was conjugated to DOTA chelators for complexing ¹¹¹In or ¹⁷⁷Lu (panitumumab-DOTA-[¹¹¹In]In and panitumumab-DOTA-[¹⁷⁷Lu]Lu) or to a metal-chelating polymer (MCP) with multiple DOTA to bind ¹¹¹In (panitum

SUBMITTER: Aghevlian S 

PROVIDER: S-EPMC7652961 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature